Navigation Links
Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
Date:1/14/2008

CARMIEL, Israel, Jan. 14 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has signed a lease agreement for the expansion of its manufacturing and research facility. The expanded space, located in the Company's facility in Carmiel, Israel, will provide the Company with approximately three times its current manufacturing space in anticipation of the potential commercialization of the Company's lead product candidate, prGCD, a therapeutic protein for the treatment of Gaucher disease.

The term of the lease agreement is 7.5 years with options to extend the life of the lease for up to 15 additional years. The Company intends to use the expanded facility for the manufacture of prGCD. The Company expects the facility to continue enjoying the Approved Enterprise status originally granted to the facility by the Investment Center of the Israeli Ministry of Industry, Trade and Labor. Under Israel's Law for the Encouragement of Capital Investments, 1959, the income from an Approved Enterprise will be exempt from taxation in Israel for a period of 10 years, commencing with the year in which taxable income is first generated from the Approved Enterprise.

Commenting on the expansion of the manufacturing facility, Yossi Maimon, the Company's Chief Financial Officer, said, "In light of the progress we have made to date in our prGCD program, we determined that we should commence the expansion of our current facility. Our expanded facility will provide us with the space and capacity required to bring prGCD to market and meet the anticipated demand for the drug following its anticipated approval by the United States Food and Drug Administration, while continuing to advance the research of the additiona
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
2. Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference
3. Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock
4. Protalix BioTherapeutics Announces Public Offering of Common Stock
5. Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
9. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
10. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
11. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Research and Markets ( ... "Global Bioinformatics Market Outlook 2019" report to their ... mark of around US$ 3.7 Billion in 2013 with ... around 19% during 2015-2019 The report is ... of global developments and opportunities listed in the section ...
(Date:4/21/2015)... 21, 2015 Research and Markets ... the "Complete 2015-16 Induced Pluripotent Stem Cell ... Stem cell research and experimentation have ... as stem cells have the unique ability to ... nature allows them to differentiate into a wide ...
(Date:4/21/2015)... , April 21, 2015 The ... $313.0 million in 2014 to $605.1 million by 2019, at ... Browse through the TOC of ... analysis of the industry trends and segments, with help ... Early buyers will receive 10% ...
(Date:4/21/2015)... Contract Research Organization XenoTech, LLC , a division of ... ft2 facility. The planned move will double the size ... St. in Lenexa, KS. The new facility, boasting nearly ... remain in the Kansas City metro area, just blocks away ... ago. Remaining in the Kansas City area maintains the ...
Breaking Biology Technology:Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 2Global Bioinformatics Market Outlook Report 2014-2019 - The US$ 3.7 Billion Market is Expected to Grow at a CAGR of 19% during 2015-2019 3Global Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 2North America Biostimulants Market is Expected to Reach $605.1 Million by 2019, at a CAGR of 14.1% From 2014 to 2019 3XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3
... 7 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) announced ... to present a corporate overview at the,ThinkEquity Partners, G5: ... p.m. Eastern Time (10:30 a.m. Pacific Time) at the ... the live audio broadcast or the subsequent archived,recording, log ...
... and Risk ... Distant Sites, REHOVOT, Israel and NEW YORK, September 7 ... in the field of,microRNA and RNAi, announced today it will ... significant potential of microRNA,profiles to develop a diagnostic test for ...
... 5:30-7:30 p.m. (ET), SAN DIEGO, Sept. 7 ... developing products for,minimally disruptive surgical treatments for the spine, ... institutional investors and,analysts at the Waldorf=Astoria Hotel in New ... to 7:30 p.m. ET. The reception will be ...
Cached Biology Technology:Monogram Biosciences to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 2NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 3NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 4NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma 5NuVasive to Host Investor Reception on September 11, 2007 2NuVasive to Host Investor Reception on September 11, 2007 3NuVasive to Host Investor Reception on September 11, 2007 4
(Date:4/1/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces the second shipment of a ... early access pre-order customers. Feedback from ... including Walmart, Target, AT&T, Dunkin, Donuts, Stop & Shop ... all outlets and very easy to use. Several users ...
(Date:3/30/2015)... and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has announced ... in Automotive Sector 2014-2018" report to their offering. ... market in Automotive Sector to grow at a CAGR ... recognition is the ability of a device to identify ... recognition technology can be 2D-based or 3D-based. It uses ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... United States and Europe has identified a single genetic mutation ... with and without diabetes. Albuminuria is a condition caused by ... is an indication of kidney disease. The research team, ... association studies to identify missense variant (I2984V) in the CUBN ...
... tiniest pollution particles which we take in with ... people more vulnerable to cardiovascular and respiratory problems. While ... showing exactly how it does so has been challenging. ... Environmental Health Perspectives , scientists showed that in ...
... an estimated 10,000 shipping containers fall off container ships at ... for months, most eventually sink to the seafloor. No one ... deep seafloor. From March 8 to March 10, 2011, ... National Marine Sanctuary (MBNMS) will use a robotic submarine to ...
Cached Biology News:Gene variant influences chronic kidney disease risk 2Pinpointing air pollution's effects on the heart 2Pinpointing air pollution's effects on the heart 3MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 2MBARI and Monterey Bay National Marine Sanctuary to study effects of shipping containers lost at sea 3
Recombinant Mouse Noggin...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Human VASA Biotinylated Affinity Purified PAb...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Biology Products: